drugset
drugset / Trial / NCT00906945

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

NCT00906945 ↗

Phase 1/2 Completed 39 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.

Timeline

Start
2011-02
Primary completion
2012-11
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject G-CSF Unknown 10 ug/kg Subcutaneous
Subject Plerixafor Small molecule 240 ug/kg Intravenous
Subject Plerixafor Small molecule 320 ug/kg Intravenous
Subject Plerixafor Small molecule 420 ug/kg Intravenous
Subject Plerixafor Small molecule 560 ug/kg Intravenous
Subject Plerixafor Small molecule 750 ug/kg Intravenous
Background Cytarabine Small molecule 1000 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Mitoxantrone Small molecule 8 mg/m2 Intravenous

Indications

acute myeloid leukemia